Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8. (Q42977931)

12 November 2017

title

Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8. (English)

1 reference

12 November 2017

1 reference

1 reference

Yoshio Tokumoto

1

1 reference

12 November 2017

Yoichi Hiasa

2

1 reference

12 November 2017

Kazuhiro Uesugi

3

1 reference

12 November 2017

Takao Watanabe

4

1 reference

12 November 2017

Toshie Mashiba

5

1 reference

12 November 2017

Masanori Abe

6

1 reference

12 November 2017

Teru Kumagi

7

1 reference

12 November 2017

Yoshio Ikeda

8

1 reference

12 November 2017

Bunzo Matsuura

9

1 reference

12 November 2017

Morikazu Onji

10

1 reference

12 November 2017

language of work or name

English

0 references

publication date

21 February 2012

1 reference

Journal of Infectious Diseases

12 November 2017

published in

1 reference

12 November 2017

volume

205

1 reference

12 November 2017

issue

7

1 reference

12 November 2017

page(s)

1121-1130

1 reference

Epidemiology of hepatitis C: geographic differences and temporal trends

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Evasion of intracellular host defence by hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Hepatitis C virus expression and interferon antiviral action is dependent on PKR expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Cell-based models of sustained, interferon-sensitive hepatitis C virus genotype 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Ribavirin improves early responses to peginterferon through improved interferon signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Hepatitis C virus core protein induces neuroimmune activation and potentiates Human Immunodeficiency Virus-1 neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Relationships between Hepatitis C Virus Replication and CXCL-8 Production In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

AP-1 function and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIS025

21 January 2018

Identifiers

DOI

10.1093/INFDIS/JIS025

1 reference

12 November 2017

1 reference